Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. NVCN

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Comment by Barewoodon Apr 06, 2018 11:48pm
150 Views
Post# 27846693

RE:There are some people about to faceplant into a wall

RE:There are some people about to faceplant into a wallWhat we have here Folks is a genuine unadulterated pure bread Basher! I think I will take advice from the experts and top of the line analysts. This Basher has not provided a spec of evidence in its claims. Thomson Reuters still maintains a "Strong Buy" recommendation and has a price target within the next 12 months anywhere from $0.50 to $3.25 or a 4429% increase. Both the Earnings and Relative Valuation for Neovasc are ranked at the high end at 8 and 10 with 10 being the highest. For the sake of argument Great Basin is no comparison for Neovasc.
<< Previous
Bullboard Posts
Next >>